Preservation of β-cell function: The key to diabetes prevention

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 8, 2011, Pages 2354-2366

  DeFronzo, Ralph A ^a   Abdul Ghani, Muhammad A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE; VOGLIBOSE;

CELL FUNCTION; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIET THERAPY; DISEASE COURSE; DRUG COST; DRUG EFFICACY; EXERCISE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEDICAL SOCIETY; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; UNITED STATES; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; PREDIABETIC STATE;

EID: 79960773090     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0246     Document Type: Review

References (134)

1. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf
2. Wild S, Roglic G, Green A, Sicree R, King H 2004 Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053
3. The Diabetes Control and Complications Trial Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
4. UK Prospective Diabetes Study Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
5. UK Prospective Diabetes Study 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865
6. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M 1995 Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117
7. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR 2000 Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412 (Pubitemid 30609442)
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 2008 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589
9. American Diabetes Association 2011 Standards of medical care in diabetes. Diabetes Care 34:S11-S61
10. Grant RW, Buse JB, Meigs JB 2005 Quality of diabetes care in U.S. academic medical centers. Diabetes Care 28:337-442
11. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS 2009 Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 122:443-453
12. Turner RC, Cull CA, Frighi V, Holman RR 1999 Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012 (Pubitemid 29254858)
13. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR 1998 β-Cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 15:290-296 (Pubitemid 28168508)
14. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA 2005 β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes mellitus: a new analysis. J Clin Endocrinol Metab 90:493-500 (Pubitemid 40116699)
15. Abdul-Ghani MA, Tripathy D, DeFronzo RA 2006 Contribution of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29:1130-1139 (Pubitemid 44115261)
16. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA 2006 Insulin secretion and insulin action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study (VAGES). Diabetes 55:1430-1435 (Pubitemid 44195383)
17. Weyer C, Tataranni PA, Bogardus C, Pratley RE 2001 Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24:89-94
18. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403 (Pubitemid 34437694)
19. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE 2005 Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes 54:1150-1156 (Pubitemid 40446330)
20. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR 2006 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368:1096-1105
21. Cowie CC, Harris MI, Silverman RE, Johnson EW, Rust KF 1993 Effect of multiple risk factors on differences between blacks and whites in the prevalence of non-insulin-dependent diabetes mellitus in the United States. Am J Epidemiol 137:719-732 (Pubitemid 23145427)
22. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK 1990 Incidence of type II diabetes in Mexican Americans: predicted by fasting insulin and glucose, obesity and body fat distribution. Diabetes 39:283-288 (Pubitemid 20076210)
23. DeFronzo RA, Ferrannini E 1991 Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and ASCVD. Diabetes Care 14:173-194
24. Reaven GM 1988 Banting lecture. Role of insulin resistance in human disease. Diabetes 37:1595-1607 (Pubitemid 19004941)
25. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Järvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C 1988 Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217-1225
26. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH 1988 The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 319:1500-1506 (Pubitemid 19003408)
27. DeFronzo RA 1997 Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177-285
28. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, Gerich J 1995 Pancreatic β-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 273:1855-1861
29. Polonsky KS, Sturis J, Bell GI 1996 Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the β-cell to compensate for insulin resistance. N Engl J Med 334:777-783 (Pubitemid 26089361)
30. Buchanan TA, Xiang A, Kjos SL, Lee WP, Trigo E, Nader I, Bergner EA, Palmer JP, Peters RK 1998 Gestational diabetes: antepartum characteristics that predict postpartum glucose intolerance and type 2 diabetes in Latino women. Diabetes 47:1302-1310 (Pubitemid 28357009)
31. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP 2002 Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacologic treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803 (Pubitemid 34970933)
32. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J 1999 Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141-146 (Pubitemid 29028311)
33. 1976 Ten-year follow-up report on Birmingham Diabetes Survey of 1961. Report by the Birmingham Diabetes Survey Working Party. Br Med J 2:35-37
34. Keen H, Jarrett RJ, McCartney P 1982 The ten-year follow-up of the Bedford Survey. Diabetologia 22:73-78
35. Sasaki A, Suzuki T, Horiuchi N 1982 Development of diabetes in Japanese subjects with impaired glucose tolerance: a seven-year follow-up study. Diabetologia 22:154-157 (Pubitemid 12183670)
36. Lee ET, Howard BV, Savage PJ, Cowan LD, Fabsitz RR, Oopik AJ, Yeh J, Go O, Robbins DC, Welty TK 1995 Diabetes and impaired glucose tolerance in three American Indian populations aged 45-74 years. Diabetes Care 18:599-610
37. Jarrett RJ, Keen H, McCartney P 1984 The Whitehall study: ten year follow-up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death. Diabetic Med 1:279-283 (Pubitemid 15194339)
38. Eriksson KF, Lindgärde F 1991 Prevention of type 2 diabetes by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia 34:891-898
39. Ferrannini E, Gastaldelli A, Matsuda M, Miyazaki Y, Pettiti M, Glass L, DeFronzo RA 2003 Influence of ethnicity and familial diabetes on glucose tolerance and insulin action. A physiological analysis. J Clin Endocrinol Metab 88:3251-3257 (Pubitemid 36877501)
40. DeFronzo RA 1988 Lilly lecture. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687 (Pubitemid 19043172)
41. Defronzo RA 2009 Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes. Diabetes 58:773-795
42. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Charles MA, Bennett PH 1991 A two-step model for development of non-insulin-dependent diabetes. Am J Med 90:229-235
43. Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L 2009 Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care 32:281-286
44. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF 1997 Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46:701-710 (Pubitemid 27143390)
45. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP 2005 Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54:333-339
46. Kolberg JA, Jørgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, Rowe MW, Urdea MS, Xu XM, Hansen T, Pedersen O, Borch-Johnsen K 2009 Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter 99 cohort. Diabetes Care 32:1207-1212
47. Abdul-Ghani MA, Abdul-Ghani T, Ali N, Defronzo RA 2008 One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 31:1650-1655
48. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M 2007 What is the best predictor of future type 2 diabetes? Diabetes Care 30:1544-1548 (Pubitemid 46871168)
49. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350 (Pubitemid 32378388)
50. Ratner RE 2006 An update on the diabetes prevention program. Endocr Pract 12(Suppl 1):20-24 (Pubitemid 44963606)
51. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD 2011 Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104-1115
52. Jallut D, Golay A, Munger R, Frascarolo P, Schutz Y, Jéquier E, Felber JP 1990 Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism. Metabolism 39:1068-1075 (Pubitemid 20351266)
53. Bajaj M, Defronzo RA 2003 Metabolic and molecular basis of insulin resistance. J Nucl Cardiol 10:311-323 (Pubitemid 36758077)
54. DeFronzo RA, Ferrannini E, Simonson DC 1989 Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387-395 (Pubitemid 19105727)
55. Pratipanawatr W, Pratipanawatr T, Cusi K, Berria R, Adams JM, Jenkinson CP, Maezono K, DeFronzo RA, Mandarino LJ 2001 Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated IRS-1 tyrosine phosphorylation. Diabetes 50:2572-2578 (Pubitemid 33642776)
56. Abdul-Ghani MA, Matsuda M, Jani R, Jenkinson CP, Coletta DK, Kaku K, DeFronzo RA 2008 The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab 295:E401-E406
57. Godsland IF, Jeffs JA, Johnston DG 2004 Loss of β-cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47:1157-1166 (Pubitemid 39093312)
58. Weyer C, Bogardus C, Mott DM, Pratley RE 1999 The natural history of resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794
59. Rossetti L, Giaccari A, DeFronzo RA 1990 Glucose toxicity. Diabetes Care 13:610-630 (Pubitemid 20169143)
60. Bays H, Mandarino L, DeFronzo RA 2004 Role of the adipocytes, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478 (Pubitemid 38269844)
61. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ 2001 Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723 (Pubitemid 32755966)
62. Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S 2009 Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:199-207
63. Vilsbøll T, Krarup T, Madsbad S, Holst JJ 2002 Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111-1119 (Pubitemid 34985287)
64. Diamond MP, Thornton K, Connolly-Diamond M, Sherwin RS, DeFronzo RA 1995 Reciprocal variation in insulin-stimulated glucose uptake and pancreatic insulin secretion inwomenwith normal glucose tolerance. J Soc Gynecol Investig 2:708-715
65. Abdul-Ghani MA, Williams K, DeFronzo R, Stern M 2006 Risk of progression to type 2 diabetes based upon relationship between post-load plasma glucose and fasting plasma glucose. Diabetes Care 29:1613-1618 (Pubitemid 44127589)
66. Bergman RN, Finegood DT, Kahn SE 2002 The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 32(Suppl 3):35-45 (Pubitemid 41704998)
67. Kahn SE 2001 Clinical review 135. The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4058 (Pubitemid 32848511)
68. DECODE Study Group, the European Diabetes Epidemiology Group 2001 Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405
69. Kriska AM, LaPorte RE, Pettitt DJ, Charles MA, Nelson RG, Kuller LH, Bennett PH, Knowler WC 1993 The association of physical activity with obesity, fat distribution, and glucose intolerance in Pima Indians. Diabetologia 36:863-869 (Pubitemid 23248160)
70. Henry RR, Wallace P, Olefsky JM 1986 Effects of weight loss on mechanisms of hyperglycemia in obese NIDDM. Diabetes 35:990-998 (Pubitemid 16029818)
71. Koivisto VA, Yki-Järvinen H, DeFronzo RA 1986 Physical training and insulin sensitivity. Diabetes Metab Rev 1:445-481
72. Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H 2005 Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program. Effects of lifestyle intervention and metformin. Diabetes 54:2404-2414 (Pubitemid 41134269)
73. Wing RR, Goldstein MG, Acton KJ, Birch LL, Jakicic JM, Sallis Jr JF, Smith-West D, Jeffery RW, Surwit RS 2001 Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care 24:117-123 (Pubitemid 32104231)
74. Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SL, Hamman RF, Hoskin MA, Knowler WC, Ma Y; Diabetes Prevention Program Research Group 2008 First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. Int J Obes (Lond) 32:1537-1544
75. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group 2006 Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761-775 (Pubitemid 43244304)
76. Saaristo T, Moilanen L, Korpi-Hyövälti E, Vanhala M, Saltevo J, Niskanen L, Jokelainen J, Peltonen M, Oksa H, Tuomilehto J, Uusitupa M, Keinänen-Kiukaanniemi S 2010 Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care 33:2146-2151
77. DeFronzo RA, Goodman AM 1995 Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 333:541-549
78. DeFronzo RA, Barzilai N, Simonson DC 1991 Mechanisms of metformin action in NIDDM. J Clin Endocrinol Metab 73:1294-1301
79. Cusi K, DeFronzo RA 1998 Metformin: a review of its metabolic effects. Diabetes Rev 6:89-131 (Pubitemid 28554676)
80. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443 (Pubitemid 44903747)
81. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, Indian Diabetes Prevention Programme (IDPP) 2006 The Indian Diabetes Prevention Program shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289-297 (Pubitemid 43185397)
82. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B 2007 Impaired fasting plasma glucose and impaired glucose tolerance: implications for care. Consensus Statement from American Diabetes Association. Diabetes Care 30:753-759
83. Yki-Järvinen H 2004 Thiazolidinediones. New Engl J Med 351:1106-1118
84. Spiegelman BM 1998 PPAR-γ : adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514 (Pubitemid 28160438)
85. DeFronzo RA 2010 Insulin resistance, lipotoxicity, type 2 diabetes, and atherosclerosis: the missing links. The Claude Bernard Lecture. Diabetologia 53:1270-1287
86. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA 2007 Thiazolidinediones improve β-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 292:E871-E883 (Pubitemid 46411067)
87. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI 1998 Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872 (Pubitemid 28135963)
88. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA 2001 Improved glycemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719 (Pubitemid 32888853)
89. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA 2003 Rosiglitazone improves downstream insulin-receptor signaling in type 2 diabetic patients. Diabetes 52:1943-1950 (Pubitemid 36919785)
90. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J 1994 Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193 (Pubitemid 24331336)
91. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS 1997 Treatment with the oral antidiabetic agent troglitazone improves β-cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537 (Pubitemid 27340499)
92. Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME, Xiang A, Azen S, Buchanan TA 1996 Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM. Diabetes 45:1572-1579 (Pubitemid 26357551)
93. Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Kawakubo M, Buchanan TA 2006 Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55:517-522 (Pubitemid 43343284)
94. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH 1999 Troglitazone prevents mitochondrial alterations, β-cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 96:11513-11518 (Pubitemid 29487412)
95. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366:1279-1289 (Pubitemid 41416583)
96. Miyazaki Y, Matsuda M, DeFronzo RA 2002 Dose response effect of pioglitazone on insulin sensitivity, and insulin secretion in type 2 diabetes mellitus. Diabetes Care 25:517-523 (Pubitemid 41103346)
97. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL 2000 Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23:1605-1611
98. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ 2010 Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 376:103-111
99. Holst JJ 2006 Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 49:253-260 (Pubitemid 43185393)
100. Triplitt C, DeFronzo RA 2006 Exenatide: first-in-class incretin mimetic for the treatment of type 2 diabetes mellitus. Expert Rev Endocrinol Metab 1:329-341
101. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ 2011 Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54:10-18
102. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes mellitus. Diabetes Care 28:1092-1100 (Pubitemid 40616618)
103. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR 2009 Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90
104. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG 2008 Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24:275-286 (Pubitemid 351160260)
105. Baggio LL, Drucker DJ 2007 Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157 (Pubitemid 46711096)
106. Rask E, Olsson T, Söderberg S, Holst Jj J, Tura A, Pacini G, Ahrén B 2004 Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism 53:624-631 (Pubitemid 38596536)
107. Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B 1998 Glucagon-like peptide 1 improves the ability of the β-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes 47:1259-1265 (Pubitemid 28357003)
108. Ahrén B, Larsson H, Holst JJ 1997 Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur J Endocrinol 137:127-131 (Pubitemid 27342226)
109. Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T 2007 Reduced incretin effect in type 2 diabetes. Diabetes 56:1951-1959
110. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group 2009 Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606-1616
111. Drucker DJ 2003 Glucagon-like peptide regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17:161-171 (Pubitemid 36183142)
112. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ 2009 One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32:762-768
113. Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Jarvinen H, Diamant M 2010 Extended, 3-year, exenatide therapy shows sustainable effects on β cell disposition index in metformin treated patients with type 2 diabetes. Proc of 46th Annual Meeting of European Association for the Study of Diabetes, Stockholm, 2010 (Abstract S338)
114. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L; DURATION-1 Study Group 2008 Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240-1250
115. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group 2002 Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077 (Pubitemid 34680970)
116. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; Voglibose Ph-3 Study Group 2009 Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373:1607-1614
117. Moriya R, Shirakura T, Ito J, Mashiko S, Seo T 2009 Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab 297:E1358-E1365
118. Slack E, Hapfelmeier S, Stecher B, Velykoredko Y, Stoel M, Lawson MA, Geuking MB, Beutler B, Tedder TF, Hardt WD, Bercik P, Verdu EF, McCoy KD, Macpherson AJ 2009 Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 325:617-620
119. Diabetes Prevention Program Research Group 2007 The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabetic Med 24:137-144
120. Massin P, Lange C, Tichet J, Rosilio M, Vol S, Erginay A, Cailleau M, Eschwege E, Balkau B, The DESIR Study Group 2009 HbA1c and fasting plasma glucose are predictors of retinopathy at ten years: the French desire study. Diabetologia 52(Suppl 1):S550
121. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A 2008 Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 31:464-469
122. Buchanan TA, Xiang X 2005 Gestational diabetes mellitus. J Clin Invest 115:485-491 (Pubitemid 40322217)
123. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A, Goico J, Ochoa C, Azen SP 2000 Response of pancreatic β-cells to improved insulin sensitivity inwomenat high risk for type 2 diabetes. Diabetes 49:782-788 (Pubitemid 30339994)
124. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L 2004 XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155-161 (Pubitemid 38196725)
125. Miyazaki M, De Filippis E, Bajaj M, Wajcberg E, Glass L, Triplitt C, Cersosimo E, Mandarino LJ, DeFronzo RA 2005 Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician. Br J Diabetes Vasc Dis 5:28-35 (Pubitemid 40352807)
126. Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G, Rosiglitazone Fluid Retention Study Group 2006 Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 17:3482-3490 (Pubitemid 44865290)
127. Derosa G 2010 Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus. Comparison with other oral antihyperglycaemic agents. Drugs 70:1945-1961
128. Gallwitz B 2010 Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus. Drug Safety 33:87-100
129. Garg R, Chen W, Pendergrass M 2010 Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 33:2349-2354
130. Diabetes Prevention Program Research Group 2003 Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 26:2518-2523
131. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group 2005 The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142:323-332 (Pubitemid 40293405)
132. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, Davies MJ, Khunti K 2008 Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 336:1180-1185
133. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ 2010 Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375:1365-1374
134. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC 2003 β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110 (Pubitemid 36042113)